Page last updated: 2024-11-04

rofecoxib and Ache

rofecoxib has been researched along with Ache in 76 studies

Research Excerpts

ExcerptRelevanceReference
"The preoperative administration of rofecoxib was not effective in reducing pain in uterine curettage."9.11Prospective randomized, double-blinded, placebo-controlled trial of preoperative rofecoxib for pain relief in uterine curettage. ( Phupong, V; Poomtavorn, Y, 2005)
"5 mg/acetaminophen 325 mg combination tablets (tramadol/APAP) as add-on therapy for subjects with osteoarthritis (OA) pain inadequately controlled by COX-2 nonsteroidal antiinflammatory drugs (NSAID)."9.11Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial. ( Emkey, R; Jordan, D; Kamin, M; Rosenthal, N; Wu, SC, 2004)
"In this double-blind, randomized, two-phase study, patients with moderate to severe pain after surgical extraction of >or= 2 third molars, including one mandibular impaction, were treated with rofecoxib 50 mg, oxycodone/acetaminophen 10/650 mg (singledose phase) followed by 5/325 mg every 6h as needed (multidose phase), or placebo."9.11Comparison of rofecoxib and a multidose oxycodone/ acetaminophen regimen for the treatment of acute pain following oral surgery: a randomized controlled trial. ( Bird, SR; Black, P; Chang, DJ; Chen, E; Desjardins, PJ; Geba, GP; Petruschke, RA, 2004)
"We assessed the effect of rofecoxib, a cyclo-oxygenase-2 inhibitor, and tramadol, a centrally acting analgesic, on both delayed-onset muscle soreness (DOMS) and experimentally induced ischaemic pain."9.11Rofecoxib and tramadol do not attenuate delayed-onset muscle soreness or ischaemic pain in human volunteers. ( Fuller, A; Loram, LC; Mitchell, D, 2005)
"An open-label multicentre study was conducted in primary care centres in Spain to investigate the effect of a switch from celecoxib to rofecoxib among patients with osteoarthritis and to identify factors associated with a good response to rofecoxib treatment."9.10Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain. ( Collantes-Estevez, E; Fernandez-Perez, C, 2003)
"The present data confirm our previous observations in patients with rheumatoid arthritis, further suggesting that nimesulide represents an effective agent for the treatment of joint pain, with particular reference to the rapid onset of its analgesic effect."9.10A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee. ( Bianchi, M; Broggini, M, 2003)
"Rofecoxib effectively treated primary dysmenorrhea, and cyclooxygenase-2-derived prostanoids play a role in the pathophysiology of primary dysmenorrhea."9.09Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial. ( Cantu, N; Daniels, SE; Kotey, P; Morrison, BW; Seidenberg, B, 1999)
" In the dental pain study, total pain relief (TOTPAR) over the 6 hours after dosing was similar between 50 mg and 500 mg rofecoxib and 400 mg ibuprofen (P > ."9.09Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. ( Dallob, A; De Lepeleire, I; De Schepper, P; Ehrich, EW; Gertz, BJ; Mehlisch, DR; Porras, A; Riendeau, D; Seibold, JR; Van Hecken, A; Wittreich, J; Yuan, W, 1999)
"To assess the efficiency of paracetamol, indicated in first instance for light-to-moderate pain from hip and knee arthrosis, against rofecoxib, the COX-2 inhibitor most commonly used in Spain."8.82[Analysis of cost-minimization treatment with paracetamol or COX-2 inhibitors (rofecoxib) for pain from arthrosis of the knee or hip]. ( Lizán Tudela, L; Magaz Marqués, S; Riesgo Bucher, Y; Varela Moreno, C, 2004)
"To evaluate the efficacy of rofecoxib (Vioxx) in subpopulations of patients with osteoarthritis (OA) identified by demographic or baseline disease characteristics, or varied OA involvement."7.71Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors. ( Bolognese, J; Detora, LM; Ehrich, EW; Krupa, D; Sperling, RS, 2001)
"Pretreatment with Rofecoxib significantly reduced post-SWL pain from 5."6.74Evaluation and management of post-shock wave lithotripsy pain with third-generation lithotriptors using rofecoxib. ( Erturk, E; Greene, TD; Joseph, JV, 2009)
"Both rofecoxib and ibuprofen treatment increased the gene expression of the pro-inflammatory mediators, IL6 and CCL2 (chemokine C-C motif ligand 2), following tissue injury compared to the placebo treatment."6.73Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. ( Dionne, RA; Hamza, M; Ramsay, ES; Wahl, SM; Wang, XM; Wu, TX, 2007)
"Rofecoxib is a selective cyclo-oxygenase (COX)-2 inhibitor which has little or no effect on the COX-1 isoenzyme at doses up to 1000 mg/day."6.41Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis. ( Figgitt, DP; Matheson, AJ, 2001)
"Rofecoxib have been shown to be associated with a reduced incidence of gastric erosions on endoscopy compared to standard NSAIDs in patients with arthritis."5.32[Rofecoxib: its efficacy in rheumatoid arthritis and acute pain]. ( Morović-Vergles, J, 2003)
"We assessed the effect of rofecoxib, a cyclo-oxygenase-2 inhibitor, and tramadol, a centrally acting analgesic, on both delayed-onset muscle soreness (DOMS) and experimentally induced ischaemic pain."5.11Rofecoxib and tramadol do not attenuate delayed-onset muscle soreness or ischaemic pain in human volunteers. ( Fuller, A; Loram, LC; Mitchell, D, 2005)
"5 mg/acetaminophen 325 mg combination tablets (tramadol/APAP) as add-on therapy for subjects with osteoarthritis (OA) pain inadequately controlled by COX-2 nonsteroidal antiinflammatory drugs (NSAID)."5.11Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial. ( Emkey, R; Jordan, D; Kamin, M; Rosenthal, N; Wu, SC, 2004)
"The preoperative administration of rofecoxib was not effective in reducing pain in uterine curettage."5.11Prospective randomized, double-blinded, placebo-controlled trial of preoperative rofecoxib for pain relief in uterine curettage. ( Phupong, V; Poomtavorn, Y, 2005)
"In this double-blind, randomized, two-phase study, patients with moderate to severe pain after surgical extraction of >or= 2 third molars, including one mandibular impaction, were treated with rofecoxib 50 mg, oxycodone/acetaminophen 10/650 mg (singledose phase) followed by 5/325 mg every 6h as needed (multidose phase), or placebo."5.11Comparison of rofecoxib and a multidose oxycodone/ acetaminophen regimen for the treatment of acute pain following oral surgery: a randomized controlled trial. ( Bird, SR; Black, P; Chang, DJ; Chen, E; Desjardins, PJ; Geba, GP; Petruschke, RA, 2004)
"Patient overall pain assessment, and patient and investigator global assessments were each measured on a 100mm VAS and on a 0 to 4 point Likert scale in a 6-week OA study of rofecoxib vs placebo."5.10Response relationship of VAS and Likert scales in osteoarthritis efficacy measurement. ( Bolognese, JA; Ehrich, EW; Schnitzer, TJ, 2003)
"An open-label multicentre study was conducted in primary care centres in Spain to investigate the effect of a switch from celecoxib to rofecoxib among patients with osteoarthritis and to identify factors associated with a good response to rofecoxib treatment."5.10Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain. ( Collantes-Estevez, E; Fernandez-Perez, C, 2003)
"The present data confirm our previous observations in patients with rheumatoid arthritis, further suggesting that nimesulide represents an effective agent for the treatment of joint pain, with particular reference to the rapid onset of its analgesic effect."5.10A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee. ( Bianchi, M; Broggini, M, 2003)
"Thirty-seven percent of patients receiving placebo and 42% of patients receiving rofecoxib had significant pain (5 or greater on the visual analog pain scale)."5.10A randomized double-blind prospective study evaluating patient tolerance of transrectal ultrasound-guided biopsy of the prostate using prebiopsy rofecoxib. ( Hamawy, KJ; Moinzadeh, A; Mourtzinos, A; Triaca, V, 2003)
" In the dental pain study, total pain relief (TOTPAR) over the 6 hours after dosing was similar between 50 mg and 500 mg rofecoxib and 400 mg ibuprofen (P > ."5.09Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. ( Dallob, A; De Lepeleire, I; De Schepper, P; Ehrich, EW; Gertz, BJ; Mehlisch, DR; Porras, A; Riendeau, D; Seibold, JR; Van Hecken, A; Wittreich, J; Yuan, W, 1999)
"Rofecoxib effectively treated primary dysmenorrhea, and cyclooxygenase-2-derived prostanoids play a role in the pathophysiology of primary dysmenorrhea."5.09Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial. ( Cantu, N; Daniels, SE; Kotey, P; Morrison, BW; Seidenberg, B, 1999)
"Thirteen patients with osteoid osteoma were enrolled in a prospective trial to test whether rofecoxib, a selective cyclooxygenase-2 inhibitor, is as effective for pain control as acetylsalicylic acid."5.09Cyclooxygenase-2 inhibitor for pain management in osteoid osteoma. ( Bottner, F; Grethen, C; Lindner, N; Roedl, R; Winkelmann, W; Wortler, K, 2001)
"To assess the efficiency of paracetamol, indicated in first instance for light-to-moderate pain from hip and knee arthrosis, against rofecoxib, the COX-2 inhibitor most commonly used in Spain."4.82[Analysis of cost-minimization treatment with paracetamol or COX-2 inhibitors (rofecoxib) for pain from arthrosis of the knee or hip]. ( Lizán Tudela, L; Magaz Marqués, S; Riesgo Bucher, Y; Varela Moreno, C, 2004)
" Thus, physiological and pathophysiological roles of COX-2 were considered from the standpoint of clinical effects of the two latest COX-2 selective inhibitors, celecoxib and rofecoxib, on inflammation, pain, fever and colorectal cancer together with their adverse effects on gastrointestinal, renal and platelet functions; and the usefulness and limits of COX-2-selective inhibitors were discussed with the trends of new NSAIDs development."4.81[Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors]. ( Nakamura, H, 2001)
"Although the published literature is limited, the data indicate that rofecoxib is an effective analgesic agent for the painful conditions in which it has been studied."4.81Rofecoxib: clinical pharmacology and clinical experience. ( Weaver, AL, 2001)
"This study showed that TS has anti-visceral pain properties comparable with those of rofecoxib (a cyclooxygenase-2 inhibitor) and diclofenac, which suggests promise for the treatment of intractable visceral pain in humans."3.81Toona sinensis leaf extract has antinociceptive effect comparable with non-steroidal anti-inflammatory agents in mouse writhing test. ( Chan, TF; Hsu, HK; Hwang, SL; Lee, KS; Lieu, AS; Lin, CL; Su, YF; Yang, YC, 2015)
"The dose-response relation of S-methylisothiourea, rofecoxib, mefenamic acid, and their combination was studied in the late phase of formalin-induced pain in mice over the time spent in licking the hindpaw after formalin injection."3.74The interaction between inhibitors of nitric oxide synthase and cyclooxygenase in formalin-induced pain in mice: an isobolographic study. ( Bhat, AS; Krishna, V; Kumar, D; Prakash, VR; Tandan, SK, 2008)
"Rofecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor approved for the treatment of pain and arthritis in adults."3.72Pharmacokinetics of rofecoxib in children with sickle cell hemoglobinopathy. ( Aranda, JV; Edwards, DJ; Frattarelli, DA; Haritos, D; Prescilla, RP, 2004)
" Five days before admission, rofecoxib, a new selective COX-2 inhibitor nonsteroidal anti-inflammatory drug (NSAID), was added for leg pain."3.71Fatal hyperkalemia related to combined therapy with a COX-2 inhibitor, ACE inhibitor and potassium rich diet. ( Armoni, M; Bukish, N; Derazon, H; Hay, E; Katz, L; Kruglyakov, I, 2002)
"To evaluate the efficacy of rofecoxib (Vioxx) in subpopulations of patients with osteoarthritis (OA) identified by demographic or baseline disease characteristics, or varied OA involvement."3.71Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors. ( Bolognese, J; Detora, LM; Ehrich, EW; Krupa, D; Sperling, RS, 2001)
"Pretreatment with Rofecoxib significantly reduced post-SWL pain from 5."2.74Evaluation and management of post-shock wave lithotripsy pain with third-generation lithotriptors using rofecoxib. ( Erturk, E; Greene, TD; Joseph, JV, 2009)
"Both rofecoxib and ibuprofen treatment increased the gene expression of the pro-inflammatory mediators, IL6 and CCL2 (chemokine C-C motif ligand 2), following tissue injury compared to the placebo treatment."2.73Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. ( Dionne, RA; Hamza, M; Ramsay, ES; Wahl, SM; Wang, XM; Wu, TX, 2007)
" However, NSAIDs cause significant adverse upper gastrointestinal effects, including increased mortality from serious ulcer complications."2.41Selective inhibitors of COX-2--are they safe for the stomach? ( Giercksky, KE; Haglund, U; Rask-Madsen, J, 2000)
"Rofecoxib is a specific inhibitor of cyclooxygenase-2 (COX-2), thereby inhibiting prostanoid synthesis in cells that express COX-2, including inflammatory cells."2.41Rofecoxib. ( Furst, DE; Hillson, JL, 2000)
"Rofecoxib is a selective cyclo-oxygenase (COX)-2 inhibitor which has little or no effect on the COX-1 isoenzyme at doses up to 1000 mg/day."2.41Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis. ( Figgitt, DP; Matheson, AJ, 2001)
" During repeated dosage with the specific COX-2 inhibitors, the 24 hour urinary excretion of sodium is only inhibited for the first day of treatment while the excretion of sodium is still decreased over the first 3 hours after the individual doses."2.41Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol). ( Day, RO; Graham, GG; Graham, RI, 2002)
"Rofecoxib was used for eight acute haemarthrosis, four target joints, seven cases of synovitis and 12 episodes of pain."1.33Rofecoxib as adjunctive therapy for haemophilic arthropathy. ( Nugent, DJ; Rattray, B; Young, G, 2005)
"Rofecoxib have been shown to be associated with a reduced incidence of gastric erosions on endoscopy compared to standard NSAIDs in patients with arthritis."1.32[Rofecoxib: its efficacy in rheumatoid arthritis and acute pain]. ( Morović-Vergles, J, 2003)
"Acute inflammation was induced by sub-plantar injection of carrageenan (1%) in the rat hind paw."1.31Studies on the anti-inflammatory and anti-nociceptive effects of melatonin in the rat. ( Abdel-Salam, OM; Arbid, MS; Baiuomy, AR; El-Batran, S; El-Shenawy, SM, 2002)

Research

Studies (76)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's5 (6.58)18.2507
2000's67 (88.16)29.6817
2010's4 (5.26)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Black, WC1
Brideau, C1
Chan, CC1
Charleson, S1
Cromlish, W1
Gordon, R1
Grimm, EL1
Hughes, G1
Leger, S1
Li, CS1
Riendeau, D2
Thérien, M1
Wang, Z2
Xu, LJ1
Prasit, P1
Giblin, GM1
Billinton, A1
Briggs, M1
Brown, AJ1
Chessell, IP2
Clayton, NM1
Eatherton, AJ1
Goldsmith, P1
Haslam, C1
Johnson, MR1
Mitchell, WL1
Naylor, A1
Perboni, A1
Slingsby, BP1
Wilson, AW2
Blouin, M1
Han, Y2
Burch, J1
Farand, J1
Mellon, C1
Gaudreault, M1
Wrona, M2
Lévesque, JF2
Denis, D2
Mathieu, MC2
Stocco, R2
Vigneault, E1
Therien, A1
Clark, P1
Rowland, S2
Xu, D2
O'Neill, G1
Ducharme, Y2
Friesen, R2
Colucci, J1
Boyd, M1
Berthelette, C1
Chiasson, JF1
Therien, AG1
Clarke, P1
Werner, S1
Mesch, S1
Hillig, RC1
Ter Laak, A1
Klint, J1
Neagoe, I1
Laux-Biehlmann, A1
Dahllöf, H1
Bräuer, N1
Puetter, V1
Nubbemeyer, R1
Schulz, S1
Bairlein, M1
Zollner, TM1
Steinmeyer, A1
Su, YF1
Yang, YC1
Hsu, HK1
Hwang, SL1
Lee, KS1
Lieu, AS1
Chan, TF1
Lin, CL1
Greene, TD1
Joseph, JV1
Erturk, E1
Hay, E1
Derazon, H1
Bukish, N1
Katz, L1
Kruglyakov, I1
Armoni, M1
El-Shenawy, SM1
Abdel-Salam, OM1
Baiuomy, AR1
El-Batran, S1
Arbid, MS1
Bolognese, JA2
Schnitzer, TJ3
Ehrich, EW4
Collantes-Estevez, E1
Fernandez-Perez, C1
Bianchi, M1
Broggini, M1
Burian, M1
Geisslinger, G1
Moinzadeh, A1
Mourtzinos, A1
Triaca, V1
Hamawy, KJ1
Déciga-Campos, M1
López-Muñoz, FJ2
Emkey, R1
Rosenthal, N1
Wu, SC1
Jordan, D1
Kamin, M1
Morović-Vergles, J1
Dudhgaonkar, SP1
Kumar, D2
Naik, A1
Devi, AR1
Bawankule, DU1
Tandan, SK2
Chang, DJ1
Desjardins, PJ1
Bird, SR1
Black, P1
Chen, E1
Petruschke, RA2
Geba, GP2
White, WB1
Jayr, C2
Tran, F1
Boggie, DT1
Delattre, ML1
Schaefer, MG1
Morreale, AP1
Plowman, BK1
Prescilla, RP1
Frattarelli, DA1
Haritos, D1
Aranda, JV1
Edwards, DJ1
Brune, K2
Zacher, J1
Gallagher, RM1
Lizán Tudela, L1
Magaz Marqués, S1
Varela Moreno, C1
Riesgo Bucher, Y1
Spake, A1
Flynn, J1
Torg, J1
Mamdani, M1
Rattray, B1
Nugent, DJ1
Young, G1
Weaver, AL2
Polis, AB1
Moore, RA1
Edwards, JE1
McQuay, HJ1
Poomtavorn, Y1
Phupong, V1
Medhurst, SJ1
Dixon, CI1
Bontoft, NC1
Winyard, LA1
Brackenborough, KT1
De Alba, J1
Clarke, CJ1
Gunthorpe, MJ1
Hicks, GA1
Bountra, C1
McQueen, DS1
Loram, LC1
Mitchell, D1
Fuller, A1
Kumar, VL1
Roy, S1
Sehgal, R1
Padhy, BM1
Wang, XM1
Wu, TX1
Hamza, M1
Ramsay, ES1
Wahl, SM1
Dionne, RA1
Underwood, A1
Murase, A1
Okumura, T1
Sakakibara, A1
Tonai-Kachi, H1
Nakao, K1
Takada, J1
Bhat, AS1
Krishna, V1
Prakash, VR1
Dallob, A1
De Lepeleire, I1
Van Hecken, A1
Yuan, W1
Porras, A1
Wittreich, J1
Seibold, JR1
De Schepper, P1
Mehlisch, DR1
Gertz, BJ1
Morrison, BW1
Daniels, SE1
Kotey, P1
Cantu, N1
Seidenberg, B1
Rodgers, E1
Miller, JL1
Hinz, B1
Giercksky, KE1
Haglund, U1
Rask-Madsen, J1
Cannon, GW1
Breedveld, FC1
Hillson, JL1
Furst, DE1
Stichtenoth, DO1
Frölich, JC1
Stienburg, KL1
Matheson, AJ1
Figgitt, DP1
Comarow, A1
Adler, J1
Nakamura, H1
Kessenich, CR1
Detora, LM1
Krupa, D1
Bolognese, J1
Sperling, RS1
Bottner, F1
Roedl, R1
Wortler, K1
Grethen, C1
Winkelmann, W1
Lindner, N1
Sirakov, M1
Martínez, RV1
Reval, M1
Campos, MD1
Terrón, JA1
Domínguez, R1
Graham, GG1
Graham, RI1
Day, RO1
Lundmark, J1
Gunnarsson, T1
Bengtsson, F1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Study to Evaluate the Efficacy of Rofecoxib and a Dosing Regimen of Oxycodone With Acetaminophen Over 24 Hours in Patients With Postoperative Dental Pain[NCT00092313]Phase 3271 participants (Actual)Interventional2002-06-30Completed
Efficacy for Acute Pain Alleviation of 50 mg Diclofenac 1 Hour Prior to Endometrial Sampling in Cases of Abnormal Uterine Bleeding[NCT01762306]90 participants (Anticipated)Interventional2012-11-30Recruiting
The Effects of Bariatric Surgery Weight Loss on Knee Pain in Patients With Osteoarthritis of the Knee[NCT00752765]30 participants (Anticipated)Observational2008-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

17 reviews available for rofecoxib and Ache

ArticleYear
[Clinical pharmacology of the selective COX-2 inhibitors].
    Der Orthopade, 2003, Volume: 32, Issue:12

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis

2003
[Analgesic effects of cyclooxygenase 2 inhibitors].
    Bulletin du cancer, 2004, Volume: 91 Spec No

    Topics: Acute Disease; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Cycl

2004
[Analysis of cost-minimization treatment with paracetamol or COX-2 inhibitors (rofecoxib) for pain from arthrosis of the knee or hip].
    Atencion primaria, 2004, Volume: 34, Issue:10

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Costs and Cost Analysis; Cyclooxygenase 2; Cyclooxygenase 2

2004
[Analgesic effects of cyclooxygenase 2 inhibitors].
    Bulletin du cancer, 2004, Volume: 91 Suppl 2

    Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Female; H

2004
Acute pain: individual patient meta-analysis shows the impact of different ways of analysing and presenting results.
    Pain, 2005, Volume: 116, Issue:3

    Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Humans; Ibuprofen; Lact

2005
Treating pain with COX-2 inhibitors.
    The Nurse practitioner, 1999, Volume: 24, Issue:11

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Drug Costs; Drug Inte

1999
Selective inhibitors of COX-2--are they safe for the stomach?
    Scandinavian journal of gastroenterology, 2000, Volume: 35, Issue:11

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cycloox

2000
Efficacy of cyclooxygenase-2-specific inhibitors.
    The American journal of medicine, 2001, Feb-19, Volume: 110 Suppl 3A

    Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxyge

2001
Rofecoxib.
    Expert opinion on pharmacotherapy, 2000, Volume: 1, Issue:5

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cyclooxygenase 2; Cyclooxygenase 2 Inhi

2000
[Therapy with preferential and specific COX-2 inhibitors].
    Der Internist, 2001, Volume: 42, Issue:3

    Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 1; Cycl

2001
Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis.
    Drugs, 2001, Volume: 61, Issue:6

    Topics: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Tri

2001
[Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2001, Volume: 118, Issue:3

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clinical Trials as Topic; Colo

2001
Rofecoxib: clinical pharmacology and clinical experience.
    Clinical therapeutics, 2001, Volume: 23, Issue:9

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; Lactones; Osteoarthritis; Pa

2001
Cyclo-oxygenase 2 inhibitors: an important new drug classification.
    Pain management nursing : official journal of the American Society of Pain Management Nurses, 2001, Volume: 2, Issue:1

    Topics: Acute Disease; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Celecoxib; Chr

2001
COX-2 inhibitors: no pain, no heart gain?
    Harvard heart letter : from Harvard Medical School, 2001, Volume: 12, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clinical Trials as Topic; Cyclooxygenas

2001
[VIOXX--a new world without pain].
    Akusherstvo i ginekologiia, 2001, Volume: 40 Suppl 5

    Topics: Adult; Cyclooxygenase Inhibitors; Dysmenorrhea; Female; Humans; Lactones; Pain; Sulfones

2001
Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol).
    Current pharmaceutical design, 2002, Volume: 8, Issue:12

    Topics: Acetaminophen; Analgesia; Cardiovascular System; Celecoxib; Clinical Trials as Topic; Cyclooxygenase

2002

Trials

16 trials available for rofecoxib and Ache

ArticleYear
Evaluation and management of post-shock wave lithotripsy pain with third-generation lithotriptors using rofecoxib.
    Journal of endourology, 2009, Volume: 23, Issue:3

    Topics: Cyclooxygenase 2 Inhibitors; Female; Humans; Lactones; Lithotripsy; Male; Middle Aged; Multivariate

2009
Response relationship of VAS and Likert scales in osteoarthritis efficacy measurement.
    Osteoarthritis and cartilage, 2003, Volume: 11, Issue:7

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Endpoint Determination; Humans; Lacton

2003
Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain.
    Current medical research and opinion, 2003, Volume: 19, Issue:5

    Topics: Aged; Celecoxib; Cyclooxygenase Inhibitors; Female; Health Status; Humans; Lactones; Logistic Models

2003
A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee.
    Drugs, 2003, Volume: 63 Suppl 1

    Topics: Adult; Aged; Analysis of Variance; Celecoxib; Double-Blind Method; Female; Humans; Knee; Lactones; M

2003
A randomized double-blind prospective study evaluating patient tolerance of transrectal ultrasound-guided biopsy of the prostate using prebiopsy rofecoxib.
    Urology, 2003, Volume: 62, Issue:6

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Biopsy, Needle; Double-Blind Method; Humans; Lactones

2003
Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial.
    The Journal of rheumatology, 2004, Volume: 31, Issue:1

    Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors;

2004
Comparison of rofecoxib and a multidose oxycodone/ acetaminophen regimen for the treatment of acute pain following oral surgery: a randomized controlled trial.
    Current medical research and opinion, 2004, Volume: 20, Issue:6

    Topics: Acetaminophen; Acute Disease; Adolescent; Adult; Analgesics; Dose-Response Relationship, Drug; Doubl

2004
Therapeutic interchange involving replacement of rofecoxib or celecoxib with valdecoxib.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2004, Jul-01, Volume: 61, Issue:13

    Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Celecoxib; Chronic Disease; Cost Savings; Cyclooxyge

2004
Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies.
    The Journal of rheumatology, 2005, Volume: 32, Issue:6

    Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Celecoxib; Cyclooxygenase Inhibitors; Dose-Response

2005
Prospective randomized, double-blinded, placebo-controlled trial of preoperative rofecoxib for pain relief in uterine curettage.
    Archives of gynecology and obstetrics, 2005, Volume: 273, Issue:2

    Topics: Adult; Cyclooxygenase 2 Inhibitors; Dilatation and Curettage; Double-Blind Method; Female; Humans; L

2005
Rofecoxib and tramadol do not attenuate delayed-onset muscle soreness or ischaemic pain in human volunteers.
    Canadian journal of physiology and pharmacology, 2005, Volume: 83, Issue:12

    Topics: Adult; Creatine Kinase; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Exerci

2005
Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain.
    Pain, 2007, Volume: 128, Issue:1-2

    Topics: Acute Disease; Adolescent; Adult; Anti-Inflammatory Agents; Cyclooxygenase 2 Inhibitors; Cytokines;

2007
Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model.
    Clinical pharmacology and therapeutics, 1999, Volume: 65, Issue:3

    Topics: Adult; Analgesics, Non-Narcotic; Animals; CHO Cells; Cricetinae; Cyclooxygenase Inhibitors; Dinopros

1999
Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial.
    Obstetrics and gynecology, 1999, Volume: 94, Issue:4

    Topics: Adolescent; Adult; Cyclooxygenase Inhibitors; Dysmenorrhea; Female; Humans; Lactones; Pain; Sulfones

1999
Precision of composite measures of osteoarthritis efficacy in comparison to that of individual endpoints.
    The Journal of rheumatology, 2001, Volume: 28, Issue:12

    Topics: Analgesics; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Humans

2001
Cyclooxygenase-2 inhibitor for pain management in osteoid osteoma.
    Clinical orthopaedics and related research, 2001, Issue:393

    Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bone Neoplasms; Cyclooxygenase

2001

Other Studies

43 other studies available for rofecoxib and Ache

ArticleYear
3,4-Diaryl-5-hydroxyfuranones: highly selective inhibitors of cyclooxygenase-2 with aqueous solubility.
    Bioorganic & medicinal chemistry letters, 2003, Mar-24, Volume: 13, Issue:6

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Chemical Phenomena; Chemi

2003
Discovery of 1-[4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a brain penetrant 5-azaindole CB2 agonist for the treatment of chronic pain.
    Journal of medicinal chemistry, 2009, Oct-08, Volume: 52, Issue:19

    Topics: Aminopyridines; Animals; Aza Compounds; Brain; Cell Line; CHO Cells; Chronic Disease; Cricetinae; Cr

2009
The discovery of 4-{1-[({2,5-dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl}carbonyl)amino]cyclopropyl}benzoic acid (MK-2894), a potent and selective prostaglandin E2 subtype 4 receptor antagonist.
    Journal of medicinal chemistry, 2010, Mar-11, Volume: 53, Issue:5

    Topics: Analgesics; Animals; Benzoates; Cyclopropanes; Half-Life; Humans; Magnetic Resonance Spectroscopy; M

2010
Discovery of 4-[1-[([1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl]carbonyl)amino]cyclopropyl]benzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain.
    Bioorganic & medicinal chemistry letters, 2010, Jun-15, Volume: 20, Issue:12

    Topics: Animals; Arthritis; Benzoates; Cells, Cultured; Dogs; Drug Discovery; Drug Stability; Hepatocytes; H

2010
Discovery and Characterization of the Potent and Selective P2X4 Inhibitor
    Journal of medicinal chemistry, 2019, 12-26, Volume: 62, Issue:24

    Topics: Acetamides; Animals; Apoptosis; Cell Proliferation; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochr

2019
Toona sinensis leaf extract has antinociceptive effect comparable with non-steroidal anti-inflammatory agents in mouse writhing test.
    BMC complementary and alternative medicine, 2015, Mar-19, Volume: 15

    Topics: Acetic Acid; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Cycloox

2015
Fatal hyperkalemia related to combined therapy with a COX-2 inhibitor, ACE inhibitor and potassium rich diet.
    The Journal of emergency medicine, 2002, Volume: 22, Issue:4

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cyclooxygenase Inhibitors; Diet; Drug Interactions;

2002
[No chance for pain. Rofecoxib eases not only tooth extraction].
    MMW Fortschritte der Medizin, 2002, Jun-27, Volume: 144, Issue:26

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; La

2002
Studies on the anti-inflammatory and anti-nociceptive effects of melatonin in the rat.
    Pharmacological research, 2002, Volume: 46, Issue:3

    Topics: Administration, Topical; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal;

2002
[Information on preoperative analgesia. Acute pain therapy with rofecoxib].
    Schmerz (Berlin, Germany), 2003, Volume: 17, Issue:1

    Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Humans; Lactones; Pain; Preoperative Care; S

2003
[Selective COX 2 inhibitor rofecoxib. To "defy" the pain].
    MMW Fortschritte der Medizin, 2003, Aug-07, Volume: 145, Issue:31-32

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors

2003
[Meta-analysis on acute pain. Rofecoxib helped three quarters of patients].
    MMW Fortschritte der Medizin, 2003, Aug-07, Volume: 145, Issue:31-32

    Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Data Interpretati

2003
Participation of the NO-cyclic GMP pathway in rofecoxib-induced antinociception.
    Proceedings of the Western Pharmacology Society, 2003, Volume: 46

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arginine; Cyclic GMP; Cyclooxygenase 2; Cyclooxyge

2003
[Rofecoxib: its efficacy in rheumatoid arthritis and acute pain].
    Reumatizam, 2003, Volume: 50, Issue:2

    Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibi

2003
Interaction of inducible nitric oxide synthase and cyclooxygenase-2 inhibitors in formalin-induced nociception in mice.
    European journal of pharmacology, 2004, May-25, Volume: 492, Issue:2-3

    Topics: Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Rel

2004
[Selective COX-2 inhibitors--strong medicine for pain].
    MMW Fortschritte der Medizin, 2004, Apr-22, Volume: 146, Issue:17

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Humans

2004
Hypertension associated with therapies to treat arthritis and pain.
    Hypertension (Dallas, Tex. : 1979), 2004, Volume: 44, Issue:2

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agent

2004
[General practice study of therapy of acute pain. Patients prefer cox-2 inhibitors].
    MMW Fortschritte der Medizin, 2004, May-20, Volume: 146, Issue:21

    Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Cyclooxygenase Inh

2004
Pharmacokinetics of rofecoxib in children with sickle cell hemoglobinopathy.
    Journal of pediatric hematology/oncology, 2004, Volume: 26, Issue:10

    Topics: Administration, Oral; Adolescent; Analgesics, Non-Narcotic; Anemia, Sickle Cell; Anti-Inflammatory A

2004
[Cardiovascular risk: a class effect of coxibs? How to manage patients taking Vioxx?].
    MMW Fortschritte der Medizin, 2004, Oct-14, Volume: 146, Issue:42

    Topics: Colonic Polyps; Cyclooxygenase Inhibitors; Germany; Humans; Lactones; Long-Term Care; Myocardial Inf

2004
Balancing risks and benefits in pain medicine: wither Vioxx.
    Pain medicine (Malden, Mass.), 2004, Volume: 5, Issue:4

    Topics: Consumer Product Safety; Cyclooxygenase Inhibitors; Drug and Narcotic Control; Drug Industry; Humans

2004
The price of pain.
    U.S. news & world report, 2005, Jan-10, Volume: 138, Issue:1

    Topics: Cyclooxygenase Inhibitors; Humans; Lactones; Pain; Sulfones; United States

2005
Treating pain after Vioxx. Should you switch to another COX-2, a traditional non-steroidal anti-inflammatory, or acetaminophen.
    Health news (Waltham, Mass.), 2005, Volume: 11, Issue:1

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inh

2005
Easing arthritis pain in the post-Vioxx era.
    The Johns Hopkins medical letter health after 50, 2005, Volume: 16, Issue:12

    Topics: Arthritis; Cyclooxygenase Inhibitors; Humans; Lactones; Pain; Sulfones

2005
Vioxx and Merck: a preventable situation?
    Orthopedics, 2005, Volume: 28, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Drug Industry; Humans; Hypertensi

2005
The changing landscape for COX-2 inhibitors: a summary of recent events.
    Healthcare quarterly (Toronto, Ont.), 2005, Volume: 8, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Drug and Narcotic Control; Human

2005
Rofecoxib as adjunctive therapy for haemophilic arthropathy.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2005, Volume: 11, Issue:3

    Topics: Acute Disease; Adjuvants, Pharmaceutic; Administration, Oral; Adolescent; Adult; Anti-Inflammatory A

2005
An animal model of chronic inflammatory pain: pharmacological and temporal differentiation from acute models.
    European journal of pain (London, England), 2006, Volume: 10, Issue:6

    Topics: Animals; Arthritis; Chronic Disease; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Freund's A

2006
A comparative study on the efficacy of rofecoxib in monoarticular arthritis induced by latex of Calotropis procera and Freund's complete adjuvant.
    Inflammopharmacology, 2006, Volume: 14, Issue:1-2

    Topics: Administration, Oral; Animals; Arthritis, Experimental; Calotropis; Cyclooxygenase 2 Inhibitors; Fem

2006
Life after Vioxx.
    Newsweek, 2005, Jan-31, Volume: 145, Issue:5

    Topics: Arthritis; Cyclooxygenase 2 Inhibitors; Dietary Supplements; Drug and Narcotic Control; Humans; Infl

2005
Effect of prostanoid EP4 receptor antagonist, CJ-042,794, in rat models of pain and inflammation.
    European journal of pharmacology, 2008, Feb-02, Volume: 580, Issue:1-2

    Topics: Administration, Oral; Analgesics; Animals; Anti-Inflammatory Agents; Benzamides; Benzoates; Cell Lin

2008
The interaction between inhibitors of nitric oxide synthase and cyclooxygenase in formalin-induced pain in mice: an isobolographic study.
    Anesthesia and analgesia, 2008, Volume: 106, Issue:3

    Topics: Animals; Behavior, Animal; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxy

2008
Rofecoxib for osteoarthritis and pain.
    The Medical letter on drugs and therapeutics, 1999, Jul-02, Volume: 41, Issue:1056

    Topics: Analgesics; Cyclooxygenase Inhibitors; Diarrhea; Drug Interactions; Dyspepsia; Edema; Enzyme Inhibit

1999
Second selective COX-2 inhibitor receives marketing approval.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1999, Jul-01, Volume: 56, Issue:13

    Topics: Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors;

1999
[Gastric protective pain therapy. What is the advantage of new COX-2 inhibitors?].
    MMW Fortschritte der Medizin, 2000, Mar-16, Volume: 142, Issue:11

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C

2000
Rofecoxib (Vioxx): a year in review.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2001, Apr-03, Volume: 164, Issue:7

    Topics: Adverse Drug Reaction Reporting Systems; Canada; Cardiovascular Diseases; Enzyme Inhibitors; Humans;

2001
Pain relief at a price. A blow to the heart?
    U.S. news & world report, 2001, Sep-03, Volume: 131, Issue:8

    Topics: Arthritis; Cardiovascular Diseases; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors;

2001
Arthritis: what it is, why you get it and how to stop the pain.
    Newsweek, 2001, Sep-03, Volume: 138, Issue:10

    Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement; Celecoxib; Cyclooxy

2001
Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors.
    The Journal of rheumatology, 2001, Volume: 28, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; D

2001
[Effective not only in rheumatism and arthrosis. Rofecoxib fights also acute pain].
    MMW Fortschritte der Medizin, 2002, Feb-14, Volume: 144, Issue:7

    Topics: Acetaminophen; Acute Disease; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents

2002
Involvement of peripheral cyclooxygenase-1 and cyclooxygenase-2 in inflammatory pain.
    The Journal of pharmacy and pharmacology, 2002, Volume: 54, Issue:3

    Topics: Animals; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Female; Inflammation; Lactones

2002
[New indication for selective COX-2 inhibitors. Now also approve for acute pain].
    MMW Fortschritte der Medizin, 2002, Mar-07, Volume: 144, Issue:10

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Drug A

2002
A possible interaction between lithium and rofecoxib.
    British journal of clinical pharmacology, 2002, Volume: 53, Issue:4

    Topics: Aged; Creatinine; Depression; Drug Interactions; Humans; Lactones; Lithium; Male; Pain; Sulfones

2002